ILMN - Illumina, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
303.62
-9.13 (-2.92%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close312.75
Open311.64
Bid300.00 x 1200
Ask311.46 x 800
Day's Range301.64 - 311.64
52 Week Range207.51 - 372.61
Volume805,159
Avg. Volume1,135,722
Market Cap44.632B
Beta (3Y Monthly)1.96
PE Ratio (TTM)65.72
EPS (TTM)4.62
Earnings DateJan 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est357.67
Trade prices are not sourced from all markets
  • ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio
    Zacks22 hours ago

    ResMed Launches Nasal Mask Devise, Extends AirFit Portfolio

    ResMed's (RMD) AirFit N30i with a top-of-head connection keeps tubing out of the wearers' way, thus letting them conveniently move and sleep in any position.

  • Markit22 hours ago

    See what the IHS Markit Score report has to say about Illumina Inc.

    # Illumina Inc ### NASDAQ/NGS:ILMN View full report here! ## Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for ILMN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Negative ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ILMN totaled $1.82 billion. Additionally, the rate of outflows appears to be accelerating. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Quest Diagnostics' Core Diagnostics Strong Amid Several Woes
    Zacks2 days ago

    Quest Diagnostics' Core Diagnostics Strong Amid Several Woes

    Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.

  • Neogen Gains on Strong Genomic Arm Amid Stiff Competition
    Zacks2 days ago

    Neogen Gains on Strong Genomic Arm Amid Stiff Competition

    Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.

  • Markit4 days ago

    See what the IHS Markit Score report has to say about Illumina Inc.

    # Illumina Inc ### NASDAQ/NGS:ILMN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for ILMN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ILMN. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $5.17 billion over the last one-month into ETFs that hold ILMN are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Barrons.com4 days ago

    Five Ways to Profit from the Boom in Life Science

    Stocks of companies that make diagnostic health products have had a strong run, and with increased demand and plenty of money for R&D, more gains could be on the way.

  • Illumina (ILMN) Is Up 1.45% in One Week: What You Should Know
    Zacks5 days ago

    Illumina (ILMN) Is Up 1.45% in One Week: What You Should Know

    Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Here is Why Growth Investors Should Buy Illumina (ILMN) Now
    Zacks5 days ago

    Here is Why Growth Investors Should Buy Illumina (ILMN) Now

    Illumina (ILMN) could produce exceptional returns because of its solid growth attributes.

  • Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?
    Zacks5 days ago

    Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?

    Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.

  • Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
    Zacks5 days ago

    Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

    On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.

  • Henry Schein Animal Health Spin-Off Approaches, Cost Mounts
    Zacks6 days ago

    Henry Schein Animal Health Spin-Off Approaches, Cost Mounts

    Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.

  • Illumina (ILMN) Gains But Lags Market: What You Should Know
    Zacks7 days ago

    Illumina (ILMN) Gains But Lags Market: What You Should Know

    Illumina (ILMN) closed at $305.63 in the latest trading session, marking a +0.05% move from the prior day.

  • The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana

    The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana

  • Why You Should Consider Buying Omnicell (OMCL) Stock Now
    Zacks7 days ago

    Why You Should Consider Buying Omnicell (OMCL) Stock Now

    Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.

  • Business Wire8 days ago

    Illumina to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Tuesday, January 29, 2019

    Illumina, Inc. (ILMN) today announced that it will issue results for fourth quarter and fiscal year 2018 following the close of market on Tuesday, January 29, 2019. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s website under the “company” tab at www.illumina.com.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Illumina Inc.

    # Illumina Inc ### NASDAQ/NGS:ILMN View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for ILMN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold ILMN had net inflows of $12.68 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 5 Great Medical Stocks to Buy Ahead of Q4 Earnings
    Zacks8 days ago

    5 Great Medical Stocks to Buy Ahead of Q4 Earnings

    A Reuters review of Wall Street Research firms reveals that health care is the most favored of the S&P 500's 11 major sectors.

  • QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
    Zacks8 days ago

    QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands

    QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.

  • Here's Why You Should Invest in Illumina (ILMN) Stock Now
    Zacks9 days ago

    Here's Why You Should Invest in Illumina (ILMN) Stock Now

    Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.

  • Here's Why Illumina Gained 37.3% in 2018
    Motley Fool10 days ago

    Here's Why Illumina Gained 37.3% in 2018

    In a year characterized by market turmoil, investors found refuge in the steady and predictable DNA sequencing king.

  • Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?
    Zacks12 days ago

    Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

    Is (ILMN) Outperforming Other Medical Stocks This Year?

  • Zacks13 days ago

    Stocks Stay Positive on Trade Hopes, Still Patient Fed

    Stocks Stay Positive on Trade Hopes, Still Patient Fed

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Illumina Inc.

    # Illumina Inc ### NASDAQ/NGS:ILMN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for ILMN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding ILMN are favorable, with net inflows of $17.41 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • MarketWatch14 days ago

    Illumina sees Q4 revenue above expectations, provides a mixed outlook

    Illumina Inc. provided Wednesday a fourth-quarter revenue estimate that was above expectations, and provided a mixed outlook for 2019. The stock was still inactive in premarket trade. The genetics analysis company's Chief Executive Francis deSouza said at the J.P. Morgan Healthcare Conference that fourth-quarter revenue rose 11% from a year ago to $865 million, which was above the FactSet consensus of $862 million, while full-year revenue rose 21% to $3.3 billion. For 2019, deSouza said revenue growth is expected to be 13% to 14%, while the current FactSet consensus of $3.81 billion is about 15% above 2018 revenue of $3.3 billion. The company expects 2019 adjusted earnings per share, which excludes non-recurring items, of $6.50 to $6.60, compared with the current FactSet consensus of $6.44. Illumina's stock has lost 9.3% over the past three months, while the SPDR Health Care Select Sector ETF has declined 7.9% and the S&P 500 has shed 10.6%.

  • Why Investors Didn't Like Illumina's J.P. Morgan Presentation -- but Should Have
    Motley Fool14 days ago

    Why Investors Didn't Like Illumina's J.P. Morgan Presentation -- but Should Have

    Here's what investors should have paid attention to in Illumina CEO Francis deSouza's talk at the J.P. Morgan Healthcare Conference.